Fractyl Health (NASDAQ:GUTS) Rating Increased to Strong-Buy at Craig Hallum

Fractyl Health (NASDAQ:GUTS) was upgraded by equities research analysts at Craig Hallum to a “strong-buy” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

Other research analysts have also issued reports about the company. Canaccord Genuity Group reissued a “buy” rating and issued a $8.00 price target on shares of Fractyl Health in a research report on Thursday, March 26th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Fractyl Health in a research note on Tuesday, May 12th. HC Wainwright reiterated a “buy” rating and issued a $8.00 target price on shares of Fractyl Health in a report on Thursday, June 4th. Finally, Wall Street Zen raised shares of Fractyl Health from a “strong sell” rating to a “hold” rating in a research report on Saturday, May 16th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $5.12.

Fractyl Health Stock Down 0.9%

Shares of NASDAQ:GUTS opened at $0.79 on Wednesday. The firm has a market capitalization of $124.86 million, a PE ratio of -0.61 and a beta of 2.29. The business has a 50 day simple moving average of $0.78 and a two-hundred day simple moving average of $0.97. Fractyl Health has a 1 year low of $0.38 and a 1 year high of $2.44. The company has a debt-to-equity ratio of 1.41, a current ratio of 4.28 and a quick ratio of 4.28.

Fractyl Health (NASDAQ:GUTS) last posted its quarterly earnings results on Tuesday, May 12th. The company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.23. On average, equities analysts predict that Fractyl Health will post -0.6 EPS for the current year.

Insider Activity

In related news, Director Ian Sheffield acquired 35,000 shares of Fractyl Health stock in a transaction that occurred on Wednesday, June 10th. The shares were purchased at an average price of $0.73 per share, for a total transaction of $25,550.00. Following the completion of the transaction, the director owned 35,000 shares in the company, valued at $25,550. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director William Bradley purchased 68,493 shares of Fractyl Health stock in a transaction dated Wednesday, June 10th. The shares were bought at an average price of $0.73 per share, for a total transaction of $49,999.89. Following the acquisition, the director owned 84,622 shares in the company, valued at approximately $61,774.06. This trade represents a 424.66% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders have purchased 171,493 shares of company stock valued at $127,150. Insiders own 8.52% of the company’s stock.

Hedge Funds Weigh In On Fractyl Health

Hedge funds have recently modified their holdings of the business. FNY Investment Advisers LLC purchased a new stake in shares of Fractyl Health in the 3rd quarter valued at $31,000. Jane Street Group LLC purchased a new stake in Fractyl Health during the second quarter worth about $31,000. Accredited Investors Inc. purchased a new stake in Fractyl Health during the first quarter worth about $46,000. Scientech Research LLC acquired a new stake in shares of Fractyl Health during the third quarter worth about $49,000. Finally, Prelude Capital Management LLC acquired a new stake in shares of Fractyl Health during the third quarter worth about $55,000.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.